Form 4: Armata Pharma Director Granted Stock Options
Insider Ownership Change
Armata Pharmaceuticals, Inc. Director Todd C. Peterson was granted 25,640 stock options with an exercise price of $11.61, vesting fully on March 9, 2027.
Summary
- Todd C. Peterson, a Director of Armata Pharmaceuticals, Inc. (ARMP), was granted 25,640 stock options.
- The stock options have an exercise price of $11.61 per share.
- The options will vest in full on March 9, 2027, contingent on continuous service through that date.
- The expiration date for these options is March 9, 2036.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard compensation practices and potential alignment of director interests with long-term company performance.
Positives
- The grant of stock options to a director can align their interests with those of shareholders, incentivizing long-term company performance and value creation.
Future Outlook
The vesting schedule for the stock options indicates an expectation of continued service from Director Todd C. Peterson through March 9, 2027, to ensure full vesting.
Industry Context
StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical industries to attract and retain talent, aligning their interests with the company's long-term success and shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy | The grant of options is part of the company's compensation policy for directors, reflecting standard corporate governance practices for incentivizing leadership. | 03/09/2026 | Enhances alignment between director incentives and shareholder value. |
Related Party Transactions
- The grant of stock options to Todd C. Peterson, a Director, is considered a related party transaction as it involves compensation to an insider.
Stakeholder Impact
- Shareholders: Potential for increased alignment of the director's interests with shareholder value creation. Standard dilution risk if options are exercised.
- Director (Todd C. Peterson): Receives a significant equity incentive, tying personal wealth to company performance.
Next Steps
- Todd C. Peterson's continued service through March 9, 2027, for the options to fully vest.
- Potential exercise of options by March 9, 2036, if the stock price exceeds the exercise price.
Key Dates
| Date | Description |
|---|---|
| 03/09/2026 | Date of stock option grant. |
| 03/11/2026 | Date the Form 4 was signed and filed. |
| 03/09/2027 | Vesting date for the stock options, subject to continuous service. |
| 03/09/2036 | Expiration date of the stock options. |
Recommendation
holdThis Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for Armata Pharmaceuticals, Inc., thus a 'hold' recommendation is appropriate as it doesn't present a strong buy or sell signal.
Keywords
Armata Pharmaceuticals, ARMP, Stock Options, Director Compensation, Insider Trading, SEC Form 4, Equity Grant, Todd C. Peterson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.